Non-Cochrane · prognostic · PM42316202
Two-year follow-up outcomes of neoadjuvant therapy in oral squamous cell carcinoma: an exploratory systematic review and meta-analysis.
Wang Shuhan, Zhang Yu, Dong Yamin, et al. · BMC oral health · 2026 · PubMed · doi:10.1186/s12903-026-08737-1
Findings
Population Patients with oral squamous cell carcinoma (OSCC)
5 findings
| Neoadjuvant or preoperative therapy (chemotherapy, immunotherapy, chemoimmunotherapy, chemoradiotherapy, immunoradiotherapy) | None (single-arm pooled proportion) | Disease-free survival rate 2 years | Pooled proportion 0.407 [0.158, 0.684] Low Downgraded: imprecision, inconsistency 10 studies · 578 participants |
| Neoadjuvant or preoperative therapy (chemotherapy, immunotherapy, chemoimmunotherapy, chemoradiotherapy, immunoradiotherapy) | None (single-arm pooled proportion) | Overall survival rate 2 years | Pooled proportion 0.522 [0.242, 0.795] Low Downgraded: imprecision, inconsistency 10 studies · 578 participants |
| Neoadjuvant or preoperative therapy (chemotherapy, immunotherapy, chemoimmunotherapy, chemoradiotherapy, immunoradiotherapy) | None (single-arm pooled proportion) | Grade 3-4 treatment-related adverse events (incidence) Not specified | Pooled proportion 0.191 [0.071, 0.349] Low Downgraded: inconsistency, publication bias 9 studies · 540 participants |
| Neoadjuvant or preoperative therapy (chemotherapy, immunotherapy, chemoimmunotherapy, chemoradiotherapy, immunoradiotherapy) | None (single-arm pooled proportion) | Disease-free survival rate 1 year | Pooled proportion 0.674 [0.410, 0.892] Low Downgraded: risk of bias, inconsistency 10 studies · 578 participants |
| Neoadjuvant or preoperative therapy (chemotherapy, immunotherapy, chemoimmunotherapy, chemoradiotherapy, immunoradiotherapy) | None (single-arm pooled proportion) | Overall survival rate 1 year | Pooled proportion 0.833 [0.646, 0.962] Low Downgraded: inconsistency 10 studies · 578 participants |
Included primary studies 10
Open in Studies| Study | Year | Also included by | Outcomes it informs here | Trial data |
|---|---|---|---|---|
| Shen 2022 Neoadjuvant immunoradiotherapy in patients with locally advanced oral cavity squamous cell carcinoma: a retrospective study. PMID:35972629 | 2022 | 1 other review | not stated | not extracted yet |
| Ju 2023 A pilot study of camrelizumab with docetaxel and cisplatin for the first line treatment in recurrent/metastatic oral squamous cell… PMID:37492783 | 2023 | this review only | not stated | not extracted yet |
| Kashyap 2021 Efficacy and safety of neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin and oral metronomic chemotherapy (OMCT) in… PMID:35211194 | 2021 | this review only | not stated | not extracted yet |
| Kina 2024 Higher overall survival rates of oral squamous cell carcinoma treated with metronomic neoadjuvant chemotherapy. PMID:38590400 | 2024 | this review only | not stated | not extracted yet |
| Li 2024 Neoadjuvant chemoimmunotherapy in resectable locally advanced oral squamous cell carcinoma: a single-center retrospective cohort study. PMID:38935124 | 2025 | this review only | not stated | not extracted yet |
| Liu 2025 Neoadjuvant immunotherapy with or without chemotherapy in locally advanced oral squamous cell carcinoma: Randomized, two-arm, phase 2 trial. PMID:39889711 | 2025 | this review only | not stated | not extracted yet |
| Naruse 2021 Multicenter Retrospective Study of Weekly Cetuximab Plus Paclitaxel for Recurrent or Metastatic Oral Squamous Cell Carcinoma. PMID:34732452 | 2021 | this review only | not stated | not extracted yet |
| Stanford-Moore 2022 Adjuvant therapy improves survival in pT4aN0 oral cavity squamous cell carcinoma with bone invasion. PMID:34894450 | 2022 | this review only | not stated | not extracted yet |
| Yamakawa 2022 Multicenter retrospective study of nivolumab for recurrent/metastatic oral squamous cell carcinoma. PMID:36519515 | 2024 | this review only | not stated | not extracted yet |
| Yoshida 2020 Efficacy of adjuvant chemotherapy with S-1 in stage II oral squamous cell carcinoma patients: A comparative study using the propensity… PMID:32294127 | 2020 | this review only | not stated | not extracted yet |
Overlap with other reviews
Reviews that include the same primary studies are not independent evidence. Shared counts match studies by PMID, DOI or NCT, and otherwise by author and year (a probable match). Only the non-Cochrane dental reviews have study lists, so overlap with Cochrane reviews is not counted yet.
| Review | Shared studies | Jaccard |
|---|---|---|
| The Efficacy and Safety of Neoadjuvant Immunotherapy in Pan-Squamous Cell Carcinomas: A Meta-Analysis of Esophageal, Head and Neck,… (2026) | 1 | 0.02 |
Review question
| Element | Planned (methods) | Found (results) |
|---|---|---|
| Population | Patients aged 18 years or older with pathologically confirmed oral squamous cell carcinoma (including recurrent/metastatic or initially unresectable disease) | Patients with OSCC (n=578) |
| Intervention | Neoadjuvant or preoperative systemic or multimodal therapy | Chemoimmunotherapy (n=4 studies), chemotherapy (n=3), chemoradiotherapy (n=1), immunoradiotherapy (n=1), immunotherapy (n=1) |
| Comparison | Not specified | None (all single-arm, non-comparative) |
| Outcomes | Disease-free survival and overall survival at 1 and 2 years; grade 3-4 treatment-related adverse events | DFS and OS at 1 and 2 years; grade 3-4 TRAEs |
| Study designs | Retrospective or prospective studies with at least 14 patients and at least 2 years follow-up | 10 studies (8 retrospective, 1 prospective randomized trial, 1 prospective study) |
| Timing | Follow-up of at least 2 years; DFS and OS at 1 year and 2 years | Median follow-up 10.6 to 60 months |